Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · iShares

iShares Neuroscience and Healthcare ETF (IBRN)

Ticker IBRN · Since 2022-08-24 · · Holdings as of Jul 31, 2026

Expense ratio
0.47%$47/yr per $10k
1-yr return
−2.7%as of Dec 2024
Net assets
$5.5Mall share classes
Holdings
78

Bottom line

Is IBRN a good fund? The bottom line

IBRN is an actively managed health care sector ETF from iShares.

It charges 0.47% — about $47 a year on every $10,000 invested, cheaper than 83% of health care sector funds we track.

It returned −2.7% over one year (as of Dec 31, 2024, per its prospectus).

With $5.5 million in net assets and 78 holdings, its largest position is BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (14.6%) and the top 10 make up 56.2% of the portfolio.

What stands out

  • Low cost: cheaper than 83% of health care sector peers

What to watch

  • Concentrated: top 10 holdings are 56.2% of assets
  • Small fund ($5.5 million) — small funds are likelier to close

Updated Nov 19, 2026

What IBRN invests in

The iShares Neuroscience and Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.

The Fund seeks to track the investment results of the NYSE FactSet Global Neuro Biopharma and MedTech Index (the Underlying Index ), which measures the performance of equity securities of companies that are involved in the research, development or manufacturing of neurology biopharmaceuticals or neurological devices, as determined by ICE Data Indices, LLC or its affiliates (the Index Provider or IDI ). To be eligible for the Underlying Index, an equity security must (i) be listed in one of 44 developed and emerging market countries or regions, (ii) have a float-adjusted market capitalization of at least $100 million and (iii) have a three-month average daily trading value ( ADTV ) of at least $1 million. Existing constituents may remain in the Underlying Index with a float-adjusted market capitalization of at least $75 million and a three-month ADTV of at least $750,000 at each index…

From the fund's prospectus (filed Nov 21, 2025).

IBRN performance

Fund calendar-year total returns, 2023–2024 2023: +1.0%; 2024: −2.7% +1.0% 2023 −2.7% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
IBRN−2.7%——
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2024

Full IBRN performance history →

What IBRN costs

On a $10,000 investment, IBRN's 0.47% expense ratio costs about $47 a year. The prospectus estimates $591 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full IBRN fee table →

IBRN top 10 holdings

#Holding% of fund
1BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares14.64%
2Dianthus Therapeutics Inc5.34%
3Xenon Pharmaceuticals Inc4.87%
4Praxis Precision Medicines Inc4.87%
5Acadia Pharmaceuticals Inc.4.69%
6Arrowhead Pharmaceuticals, Inc.4.65%
7Alkermes Public Limited Company4.60%
8Scholar Rock Holding Corp4.29%
9Biogen Inc.4.18%
10Neurocrine Biosciences, Inc.4.09%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 56.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to IBRN

More funds like IBRN →

IBRN FAQ

What is the expense ratio of IBRN?
IBRN's expense ratio is 0.47%, which works out to about $47 a year for every $10,000 invested. The prospectus estimates total costs of $591 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is IBRN a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 83% of health care sector peers; concentrated: top 10 holdings are 56.2% of assets; small fund ($5.5 million) — small funds are likelier to close. This is general information, not personalized advice.
What does IBRN hold?
IBRN's largest holdings are BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (14.6%), Dianthus Therapeutics Inc (5.3%), Xenon Pharmaceuticals Inc (4.9%), Praxis Precision Medicines Inc (4.9%), Acadia Pharmaceuticals Inc. (4.7%). It holds 78 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Who manages IBRN?
IBRN is offered by iShares through iSHARES TRUST.